[{"id":"18460073-b219-4680-b839-36cecdb58964","acronym":"CALGB-40601","url":"https://clinicaltrials.gov/study/NCT00770809","created_at":"2021-01-17T17:29:01.763Z","updated_at":"2025-02-25T16:36:00.390Z","phase":"Phase 3","brief_title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00770809 - CALGB-40601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 305","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2025-02-06"},{"id":"b1b80856-36d7-4b3b-b80b-159943ef72f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329065","created_at":"2021-01-18T20:58:01.125Z","updated_at":"2025-02-25T16:44:52.494Z","phase":"Phase 2","brief_title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","source_id_and_acronym":"NCT04329065","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-06"},{"id":"c044dc83-7f98-4b8c-81bf-f2a99c8a914c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00769379","created_at":"2021-01-18T02:54:21.132Z","updated_at":"2025-02-25T16:35:59.903Z","phase":"Phase 3","brief_title":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","source_id_and_acronym":"NCT00769379","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2014","initiation":"Initiation: 11/10/2008","start_date":" 11/10/2008","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"c6f6111f-3721-44d3-8d28-6c42b01ad58a","acronym":"DESTINY-Breast11","url":"https://clinicaltrials.gov/study/NCT05113251","created_at":"2021-11-09T12:53:05.265Z","updated_at":"2025-02-25T13:54:06.394Z","phase":"Phase 3","brief_title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","source_id_and_acronym":"NCT05113251 - DESTINY-Breast11","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 927","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 03/12/2025","primary_completion_date":" 03/12/2025","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-05"},{"id":"257cca5a-c910-4b83-b699-e799dee41eab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101748","created_at":"2021-01-18T15:16:53.226Z","updated_at":"2025-02-25T13:52:17.471Z","phase":"Phase 1/2","brief_title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03101748","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 01/29/2018","start_date":" 01/29/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-13"},{"id":"0548374d-6bbb-45ae-b3fa-1857817c4f14","acronym":"MARGOT","url":"https://clinicaltrials.gov/study/NCT04425018","created_at":"2021-01-18T21:19:01.180Z","updated_at":"2025-02-25T12:27:36.881Z","phase":"Phase 2","brief_title":"MARGetuximab Or Trastuzumab (MARGOT)","source_id_and_acronym":"NCT04425018 - MARGOT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Margenza (margetuximab-cmkb) • Ogivri (trastuzumab-dkst)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 09/05/2024","primary_completion_date":" 09/05/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-10-02"},{"id":"efccfeae-b1d6-4b39-873a-d9182d5a3bf3","acronym":"NRG-BR004","url":"https://clinicaltrials.gov/study/NCT03199885","created_at":"2021-01-18T15:46:49.625Z","updated_at":"2025-02-25T12:26:43.973Z","phase":"Phase 3","brief_title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03199885 - NRG-BR004","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR • IL2","pipe":" | ","alterations":" HER-2 positive","tags":["ER • PGR • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 04/05/2019","start_date":" 04/05/2019","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 05/15/2025","study_completion_date":" 05/15/2025","last_update_posted":"2024-09-26"},{"id":"5455e56f-c7d0-43e1-93b2-556c1632eeb2","acronym":"UCLA l-08","url":"https://clinicaltrials.gov/study/NCT04285671","created_at":"2023-11-26T01:10:15.098Z","updated_at":"2024-07-02T16:34:26.639Z","phase":"Phase 1/2","brief_title":"Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04285671 - UCLA l-08","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" HER-2 • AXL","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["HER-2 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/29/2021","start_date":" 01/29/2021","primary_txt":" Primary completion: 12/02/2025","primary_completion_date":" 12/02/2025","study_txt":" Completion: 12/02/2026","study_completion_date":" 12/02/2026","last_update_posted":"2024-06-13"},{"id":"130d64cc-8174-4099-9fdc-c77e00468d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003209","created_at":"2021-01-18T09:08:50.149Z","updated_at":"2024-07-02T16:35:02.395Z","phase":"Phase 3","brief_title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02003209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TILs","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"},{"id":"c5f41829-50ce-4b6e-882c-2736b1a86fe9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01275677","created_at":"2021-01-18T05:10:25.363Z","updated_at":"2024-07-02T16:35:02.423Z","phase":"Phase 3","brief_title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","source_id_and_acronym":"NCT01275677","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3270","initiation":"Initiation: 01/06/2011","start_date":" 01/06/2011","primary_txt":" Primary completion: 07/31/2017","primary_completion_date":" 07/31/2017","study_txt":" Completion: 07/12/2024","study_completion_date":" 07/12/2024","last_update_posted":"2024-05-21"},{"id":"77303f62-6e39-4d65-a62b-36ab4c8e233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266249","created_at":"2021-01-18T20:43:47.844Z","updated_at":"2025-02-25T13:53:10.003Z","phase":"Phase 2","brief_title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","source_id_and_acronym":"NCT04266249","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • albumin-bound paclitaxel • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 2156","initiation":"Initiation: 03/13/2020","start_date":" 03/13/2020","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 12/31/2038","study_completion_date":" 12/31/2038","last_update_posted":"2024-04-18"},{"id":"7ef46664-9a37-4dc4-90b3-36eef7f2d80e","acronym":"SCHOLAR-2","url":"https://clinicaltrials.gov/study/NCT04680442","created_at":"2021-01-19T20:46:32.852Z","updated_at":"2025-02-25T13:53:34.367Z","phase":"Phase 2","brief_title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","source_id_and_acronym":"NCT04680442 - SCHOLAR-2","lead_sponsor":"Population Health Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"c5a4487c-936d-4c2d-b27e-f5b1144cbabf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083662","created_at":"2023-10-16T16:13:44.248Z","updated_at":"2024-07-02T16:35:14.906Z","phase":"Phase 2","brief_title":"Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers","source_id_and_acronym":"NCT06083662","lead_sponsor":"Korea University Guro Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Herzuma (trastuzumab-pkrb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-03-13"},{"id":"1d2920ad-7680-4e69-b51f-ddb29e043f61","acronym":"ACT","url":"https://clinicaltrials.gov/study/NCT05238831","created_at":"2023-08-08T16:08:43.868Z","updated_at":"2025-02-25T12:28:40.109Z","phase":"Phase 1","brief_title":"SMMART Adaptive Clinical Treatment (ACT) Trial","source_id_and_acronym":"NCT05238831 - ACT","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-01-23"},{"id":"d62c1b12-231e-41f3-9f47-89579c4ab1f5","acronym":"ACCRU-BR-1701","url":"https://clinicaltrials.gov/study/NCT04197687","created_at":"2021-01-18T20:27:24.447Z","updated_at":"2025-02-25T13:53:04.701Z","phase":"Phase 2","brief_title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","source_id_and_acronym":"NCT04197687 - ACCRU-BR-1701","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • HER-2/neu peptide vaccine • Leukine (sargramostim) • TPIV100"],"overall_status":"Recruiting","enrollment":" Enrollment 480","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-12-18"},{"id":"6cdd3cff-a8f2-4076-b8fb-2e4bb4de86c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04120246","created_at":"2021-01-18T20:08:08.496Z","updated_at":"2024-07-02T16:35:26.492Z","phase":"Phase 1","brief_title":"Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer","source_id_and_acronym":"NCT04120246","lead_sponsor":"Veana Therapeutics","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • GB221 (coprelotamab) • Vimo (alpha-tocopheroloxyacetic acid)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-12-12"},{"id":"7ef7f10e-8cb0-4019-a2f0-872f1ed2e859","acronym":"KCSG-HB19-14","url":"https://clinicaltrials.gov/study/NCT04722133","created_at":"2021-01-25T15:53:20.571Z","updated_at":"2024-07-02T16:35:33.889Z","phase":"Phase 2","brief_title":"Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy","source_id_and_acronym":"NCT04722133 - KCSG-HB19-14","lead_sponsor":"Yonsei University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • oxaliplatin • Herzuma (trastuzumab-pkrb) • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 06/14/2023","primary_completion_date":" 06/14/2023","study_txt":" Completion: 06/14/2023","study_completion_date":" 06/14/2023","last_update_posted":"2023-10-11"},{"id":"b909a245-5b83-441c-b5ff-fc2c571361ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04817540","created_at":"2021-03-26T15:52:38.328Z","updated_at":"2024-07-02T16:35:33.991Z","phase":"Phase 2","brief_title":"Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)","source_id_and_acronym":"NCT04817540","lead_sponsor":"Gangnam Severance Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herzuma (trastuzumab-pkrb)"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 03/30/2027","study_completion_date":" 03/30/2027","last_update_posted":"2023-10-11"},{"id":"50582c14-86ea-44cb-8fc7-88d457745d55","acronym":"","url":"https://clinicaltrials.gov/study/NCT01196390","created_at":"2021-01-17T17:23:25.790Z","updated_at":"2024-07-02T16:35:37.856Z","phase":"Phase 3","brief_title":"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer","source_id_and_acronym":"NCT01196390","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 203","initiation":"Initiation: 02/14/2011","start_date":" 02/14/2011","primary_txt":" Primary completion: 12/23/2019","primary_completion_date":" 12/23/2019","study_txt":" Completion: 08/15/2023","study_completion_date":" 08/15/2023","last_update_posted":"2023-09-07"},{"id":"36021acd-a4f5-4cb3-a9d3-c0b40bb6550b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162667","created_at":"2021-01-18T10:04:07.133Z","updated_at":"2024-07-02T16:36:06.182Z","phase":"Phase 3","brief_title":"Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer","source_id_and_acronym":"NCT02162667","lead_sponsor":"Celltrion","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herzuma (trastuzumab-pkrb)"],"overall_status":"Completed","enrollment":" Enrollment 562","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 05/26/2016","primary_completion_date":" 05/26/2016","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2022-08-03"},{"id":"4d335082-1c66-4110-a2e3-5201406c4ab1","acronym":"RTOG 0524","url":"https://clinicaltrials.gov/study/NCT00238420","created_at":"2021-01-18T00:48:23.809Z","updated_at":"2024-07-02T16:36:07.205Z","phase":"Phase 1/2","brief_title":"Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer","source_id_and_acronym":"NCT00238420 - RTOG 0524","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 07/26/2005","start_date":" 07/26/2005","primary_txt":" Primary completion: 02/05/2014","primary_completion_date":" 02/05/2014","study_txt":" Completion: 05/20/2022","study_completion_date":" 05/20/2022","last_update_posted":"2022-07-19"},{"id":"5d3a766e-ddbb-425a-9af6-240abe6dbbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03614364","created_at":"2021-01-18T17:45:46.030Z","updated_at":"2024-07-02T16:36:18.958Z","phase":"Phase 2","brief_title":"Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma","source_id_and_acronym":"NCT03614364","lead_sponsor":"Samsung Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herzuma (trastuzumab-pkrb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/20/2018","start_date":" 09/20/2018","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-01-04"},{"id":"9e574470-b55c-4fb9-ba76-d1930189d237","acronym":"KCSG-BR18-13","url":"https://clinicaltrials.gov/study/NCT03698383","created_at":"2021-01-18T18:07:34.589Z","updated_at":"2024-07-02T16:36:34.376Z","phase":"Phase 2","brief_title":"Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03698383 - KCSG-BR18-13","lead_sponsor":"Korean Cancer Study Group","biomarkers":" PIK3CA • PTEN • mTOR","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • MTOR mutation","tags":["PIK3CA • PTEN • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gedatolisib (PF-05212384) • Herzuma (trastuzumab-pkrb)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/03/2019","start_date":" 12/03/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-18"},{"id":"f4baabac-d56f-4847-a2f1-e72207388988","acronym":"N9831","url":"https://clinicaltrials.gov/study/NCT00005970","created_at":"2021-01-17T17:36:45.113Z","updated_at":"2024-07-02T16:36:41.970Z","phase":"Phase 3","brief_title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer","source_id_and_acronym":"NCT00005970 - N9831","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • Soltamox (tamoxifen citrate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 3436","initiation":"Initiation: 05/19/2000","start_date":" 05/19/2000","primary_txt":" Primary completion: 04/25/2005","primary_completion_date":" 04/25/2005","study_txt":" Completion: 01/27/2010","study_completion_date":" 01/27/2010","last_update_posted":"2020-08-14"}]